Cytomegalovirus - StatPearls - NCBI Bookshelf

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Bookshelf Search databaseBooksAll DatabasesAssemblyBiocollectionsBioProjectBioSampleBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesGTRIdentical Protein GroupsMedGenMeSHNLM CatalogNucleotideOMIMPMCProteinProtein ClustersProtein Family ModelsPubChem BioAssayPubChem CompoundPubChem SubstancePubMedSNPSRAStructureTaxonomyToolKitToolKitAllToolKitBookghSearch termSearch

• Browse Titles
• Advanced
• Help
• Disclaimer

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.

StatPearls [Internet].

Show detailsTreasure Island (FL): StatPearls Publishing; 2025 Jan-.Search term Cytomegalovirus Infections

Andrew D. Nguyen; Mahmoud Shorman.

Author Information and Affiliations

Authors

Andrew D. Nguyen1; Mahmoud Shorman.

Affiliations

1 University of Queensland

Last Update: December 13, 2025.

Continuing Education Activity

Human cytomegalovirus, also known as herpesvirus 5, is a ubiquitous virus that belongs to the Herpesviridae family, a large group of DNA viruses. Cytomegalovirus has the largest genome of any herpesvirus and has a worldwide seroprevalence of 24% to 100%. As with other herpesviruses, it establishes lifelong latency. Primary cytomegalovirus infection can manifest as either an asymptomatic infection, a flu-like syndrome, mononucleosis, or, in rare cases, other, more serious organ-specific syndromes. Following cytomegalovirus exposure, latency can allow the virus to persist in host cells. In immunocompromised patients, such as those who have undergone solid organ and hematopoietic stem cell transplantation, or those undergoing chemotherapy, cytomegalovirus can reactivate, leading to cytomegalovirus DNAemia. This can cause severe organ damage, including cytomegalovirus esophagitis and colitis. Reactivation of cytomegalovirus is associated with high morbidity and mortality and can cause rejection of transplanted organs. Cytomegalovirus can also be transmitted to the embryo in mothers with cytomegalovirus infection, potentially causing congenital cytomegalovirus. This activity reviews the role that healthcare professionals play in evaluating and treating patients with cytomegalovirus infection, empowering healthcare providers with the knowledge to care for individuals affected by this condition.

Objectives:

• Identify the epidemiology of cytomegalovirus infections, with a focus on immunosuppressed populations, including patients with HIV/AIDS and transplant recipients.
• Assess patients who are at risk for cytomegalovirus infection and those who exhibit symptoms consistent with this condition.
• Implement evidence-based therapeutic interventions for patients with cytomegalovirus infections.
• Collaborate with interprofessional teams, including infectious disease specialists, gastroenterologists, pharmacists, and transplant teams, for comprehensive care.

Access free multiple choice questions on this topic.

Introduction

Cytomegalovirus (CMV) is a double-stranded DNA virus that belongs to the family of Herpesviridae and is also known as human herpesvirus 5.[1] The CMV genome is the largest among human viruses, measuring approximately 230 kb and containing 200 genes that encode proteins.[2][3] Infection with CMV is common in both children and adults, with a worldwide seroprevalence ranging from 24% to 100%, which increases with age.[4] CMV is transmitted through the exchange of bodily fluids, including saliva, fomites, blood transfusions, and sexual contact. CMV can also be transmitted through solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT).[5] As with other herpesviruses, it establishes lifelong latency, remaining dormant in monocytes through specific mechanisms of transcriptional silencing.[1][6][7] CMV is a globally widespread virus that becomes latent after primary infection and can become reactivated in the setting of severe immunosuppression.

In immunocompetent patients, primary CMV typically causes asymptomatic disease or mild-to-moderate mononucleosis-like or flu-like syndromes, characterized by symptoms such as malaise, fever, lymphadenopathy, and arthralgia.[4] Infection with CMV is a leading cause of morbidity in immunosuppressed individuals, eg, due to HIV/AIDS, after receiving SOT and HSCT. In the latter population, CMV can cause severe organ damage and even cause rejection of the transplanted organ.[8] Additionally, mothers who become infected while they are pregnant may pass the virus to the embryo, and in some cases, this can cause congenital CMV.[4]

CMV infection is defined by the detection of active CMV replication in tissue specimens, peripheral blood, or other body fluids, irrespective of clinical manifestations. CMV disease refers to the presence of CMV infection in conjunction with clinically attributable symptoms and signs.[9] CMV disease is subclassified into CMV syndrome, characterized by nonspecific constitutional symptoms, such as fever, malaise, and lymphadenopathy, which are often accompanied by hematologic abnormalities, including leukopenia or thrombocytopenia, as well as tissue-invasive or end-organ CMV disease.[9] CMV syndrome involves direct viral-mediated injury to specific organs, including, but not limited to, the gastrointestinal (GI) tract, lungs, hepatobiliary system, renal parenchyma, myocardium, pancreas, central nervous system, and retina.[9]

Primary, but mostly reactivated, CMV can cause viremia, infecting various organs, including the eyes, stomach, esophagus, and colon, especially in patients with profound immunosuppression.[8] The 2 most common GI tract manifestations of CMV disease include CMV colitis and CMV esophagitis.[10]

Prevention of CMV viremia and CMV end-organ disease is critical, particularly in immunosuppressed patients. Key strategies include assessing CMV serostatus in both donor and recipient, along with regular monitoring for the emergence of viremia via frequent CMV DNA quantification. In high-risk populations, prophylactic strategies may include universal antiviral administration for all at-risk individuals, targeted prophylaxis for those at highest risk, or a pre-emptive approach. The pre-emptive strategy involves initiating antiviral therapy upon early detection of CMV DNAemia, before the onset of clinical disease.[8]

Etiology

CMV is a ubiquitous, double-stranded DNA virus that belongs to the Herpesviridae family and is also known as herpesvirus-5. The virus measures 180 nm in diameter and consists of a protein capsid that encapsulates a DNA core measuring 100 nm, which is further enclosed by a lipid envelope.[11] The assembly of viral proteins is essential for the formation of new capsids. This process begins with the creation of dense bodies that are larger than the virion that contain matrix proteins with CMV DNA. Additionally, there is a second type of structure that lacks CMV DNA but has a high concentration of matrix proteins, known as non-infectious enveloped particles. The DNA polymerase allows further CMV DNA synthesis by cleaving concatemeric molecules into daughter capsids. The DNA sequences are rich in guanine and cytosine, which readily bind host cell DNA. Once CMV infection is acquired, the virus can persist in cells of the myeloid lineage, resulting in lifelong viral latency as it evades the immune system through specific mechanisms of transcriptional silencing.[1][6][7] In immunocompetent individuals, CMV is maintained in a state of balance; however, when immunosuppression occurs, CMV can begin to replicate.[8] Cytotoxic CD8 T cells regularly control CMV reactivation. However, in immunosuppressed patients, such as those who have undergone SOT or HSCT, the failure of immune control and stimulated CMV replication can lead to reactivation.[12] Reactivation can occur locally at a specific organ and may be undetected by serum molecular viral load testing, or it can lead to viremia, also known as CMV DNAemia.[8]

Epidemiology

Infection with CMV is common in both children and adults and is endemic worldwide. Globally, the seroprevalence of CMV infection has been reported to range from 24% to 100%, although the data are heterogeneous.[5][13][14] A more recent systematic review and meta-analysis estimate a global prevalence of 83% in the general population, increasing to 86% among women of childbearing age.[1] Globally, the seroprevalence of CMV infection has been reported to range from 24% to 100%, although the data are heterogeneous and limited.[5][13][14] In the United States, age-adjusted CMV immunoglobulin G (IgG) seroprevalence is approximately 30% in children by age 5 and more than 50% in adults by age 40.[4] While further south in Central America, CMV seroprevalence ranges from 66% to 90% in the general population, with the prevalence increasing with age.[15][16] Further studies have determined CMV exposure to be independently associated with female sex, lower socioeconomic status, older age, lower household education, and increased crowding in households.[4][13][17]

CMV infection can occur as a primary infection, reinfection, or reactivation. CMV can be transmitted through multiple routes, primarily via bodily fluids, including saliva, fomites, blood transfusions, SOT, HSCT, breastfeeding, viral shedding in close-contact settings, perinatal transmission, and sexual contact.[18][19] CMV represents the most common opportunistic viral infection in patients who have received HSCT and SOT, and can cause a life-threatening tissue-invasive disease, most commonly in the GI tract, lungs, liver, eyes, and central nervous system.[20] CMV is the most common viral opportunistic infection in patients with HIV/AIDS and can cause severe disease in patients, especially those with profound immunosuppression with a CD4 count <50 cells/µL.[21] 

Reactivation is observed in patients who become immunocompromised and is associated with increased morbidity and mortality.[18][19]. Factors independently associated with CMV reactivation from observational studies have included higher age, lymphoid malignancies, concomitant graft-versus-host disease (GVHD), persistent lymphopenia, use of CMV seronegative donor graft in HSCTs,  hypoalbuminemia, higher creatinine level, higher and cumulative doses of prednisolone, and cyclosporine use.[22][23] The most common manifestations of CMV end-organ damage are retinitis, followed by pneumonitis, colitis, esophagitis, encephalitis, and polyneuropathy.[24][25] CMV colitis and esophagitis are the two most frequent CMV-related manifestations leading to end-organ damage.[10]

Cytomegalovirus in Transplant Patients

CMV infection and disease are important causes of morbidity and mortality in transplant recipients. CMV disease can present as CMV end-organ damage, a tissue-invasive disease, and as CMV syndrome, characterized by fever, leukopenia, and malaise.[26] Tissue-invasive disease in this population manifests as end-organ damage, including conditions such as colitis, esophagitis, pneumonitis, gastroenteritis, hepatitis, and rhinitis. Despite strategies to prevent CMV disease, CMV infection occurs in up to 50% of high-risk SOT patients, typically following organ transplantation from a CMV-seropositive donor to a CMV-seronegative recipient (D+/R−), and in 17% of CMV-seropositive recipients (R+).[20][27] Risk factors for CMV infection or disease include a D+/R− serological status, seropositive recipients, induction with mycophenolic acid, steroid or polyclonal antibodies, advanced age of donors and recipients, and a history of acute organ rejection.[28] CMV infection following SOT is associated with a heightened risk of acute rejection and graft failure, increased mortality, and greater healthcare costs due to more frequent hospital readmissions, longer inpatient stays, and overall higher hospitalization costs.[29]

Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients

CMV reactivation is a common complication following allogeneic HSCT (allo-HSCT), particularly during periods of immunosuppression. Positive CMV serology has been linked to reduced overall survival and increased non-relapse mortality, as reactivation can lead to severe end-organ disease, including pneumonia, colitis, and retinitis.[30] Beyond direct organ damage, CMV infection has also been linked to an increased risk of secondary bacterial and fungal infections, as well as a higher incidence of GVHD. This CMV section may be attributed to CMV's immunomodulatory effects, which can influence the dynamics of the immune system post-transplant. CMV serostatus is a critical determinant of post-transplant outcomes. Positive serology, particularly in the recipient, is associated with significant transplant-related morbidity and mortality.[31] The worst outcomes in terms of survival and non-relapse mortality occur in CMV seronegative donor/seropositive recipient (D−/R+) pairs, followed by seropositive donor/seropositive recipient (D+/R+) combinations.[32]

Cytomegalovirus in Patients with HIV Infection

CMV esophagitis is the second most common GI manifestation of CMV in individuals with HIV/AIDS. CMV is the most frequent viral opportunistic infection in this population, particularly when CD4+ T lymphocyte counts fall below 50 cells/mm³.[33] Hallmark symptoms of CMV esophagitis include dysphagia and odynophagia. Endoscopy with biopsy remains the gold standard for diagnosis. Endoscopic findings may include well-demarcated, vertical, single or multiple ulcers, or diffuse esophagitis, most commonly located in the mid-to-distal esophagus.[34] Other manifestations of CMV disease in patients with HIV/AIDS include CMV retinitis (most commonly observed), pneumonitis, and neurological sequelae, such as encephalitis, polyradiculopathy, and multifocal neuropathy (see Image. Cytomegalovirus Retinitis).[35][36]

Cytomegalovirus Colitis

CMV colitis occurs most commonly in immunocompromised hosts, including patients with HIV/AIDS and those who have undergone SOT, HSCT, and chemotherapy. CMV colitis accounts for up to 30% of CMV GI disease in SOT patients. The role of CMV in patients with inflammatory bowel disease (IBD) remains controversial. Whether CMV reactivation contributes to disease exacerbation in individuals with established IBD, occurs as a result of the disease or its treatment, or merely represents an incidental finding without pathogenic significance remains unclear.[37][38] In addition, in patients with IBD, studies have shown that immunosuppression from high-dose systemic corticosteroids is linked to the development of CMV colitis in patients with active ulcerative colitis.[39] Other immunomodulatory therapies used in ulcerative colitis, such as thiopurines and methotrexate, have also been associated with CMV infection, whereas anti-tumor necrosis factor agents have not shown a similar association.[40][41] Patients undergoing allo-HSCT are at increased risk for CMV infection or reactivation. However, distinguishing between GI GVHD and CMV colitis is crucial in this population. CMV reactivation in patients with severe ulcerative colitis is reported to have a prevalence of 4.5% to 16.6% and as high as 25% in patients requiring colectomy for severe colitis.[42] The CMV infection rate in patients with severe corticosteroid-refractory ulcerative colitis ranges from 20% to 40% when infection was diagnosed using antigenemia and histological examination of tissue biopsies.[43][44]

CMV colitis can also occur in healthy immunocompetent patients, and there have been increasing reports, although the incidence is rare.[45] The prevalence of CMV infection in severe acute colitis ranges from 21% to 34% in healthy individuals.[46][47] These patients are typically older adults with underlying comorbidities, and reported cases have shown an association with underlying ulcerative colitis.[39] These patients typically are asymptomatic or have self-limited disease, presenting as gastroenteritis, duodenitis, ileitis, proctitis, or exacerbation of IBD.[45] Colitis may result in a chronic infection or a lifelong carrier state with intermittent reactivation. Symptoms include diarrhea, abdominal pain, and hematochezia or melena. The outcomes are typically favorable, including resolution without antiviral treatment in nearly 25% of these patients.[48] CMV colitis should be a consideration in the differential diagnosis of hematochezia, not only in immunocompromised patients but also in immunocompetent patients, particularly in older adults with underlying comorbidities.[45]

Cytomegalovirus Esophagitis

CMV esophagitis is the third most common cause of infectious esophagitis—after Candida and HSV—and occurs predominantly in patients with profound immunosuppression, including those with HIV/AIDS or those receiving immunosuppressive therapy after SOT or HSCT. [49] Dysphagia and odynophagia are the most common presenting symptoms in CMV esophagitis, especially in the middle to distal esophagus. CMV esophagitis is associated with a poor prognosis, a risk of recurrence, and a high rate of morbidity and mortality at 12 months.[12]

Pathophysiology

The first step in CMV infection involves the binding of highly conserved glycoproteins M and B (gM and gB) to the host cell's heparan sulfate proteoglycans.[50] Glycoprotein B is also crucial for the spread of CMV from cell to cell.[50] Once CMV is transmitted, and the primary infection clears, the virus remains dormant in myeloid cells.[51] CMV can infect a large variety of cell types.[50] Additionally, it can remain latent in bone marrow progenitor cells after primary infection and replicate in various cells and tissues.[17] Viral replication and reactivation are contained primarily by cytotoxic T-cell immunity. However, when reactivation occurs, virions are released into the bloodstream and other body fluids, leading to the presence of symptoms, predominantly in immunocompromised patients.[52][53] Reactivation appears to be driven by inflammatory cytokines that stimulate the differentiation of myeloid progenitor cells into innate immune cells, such as macrophages and dendritic cells, allowing for genetic induction to promote lytic infection.[54][55] Cellular reactivation can occur without viremia, suggesting an element of immune control. When reactivation occurs with concurrent viremia, it is thought to occur most commonly in immunocompromised individuals, often triggered by co-infections or by allogeneic immune-driven responses that lead to end-organ damage.[56] Eye disease, such as CMV retinitis and immune recovery uveitis, is thought to result from lytic infection or an immune response against CMV antigens. Resultant immune activation and cytokine responses are thought to be responsible for CMV-associated promotion of atherosclerotic disease.[57]

In immunocompetent individuals, CMV replication is controlled by antibodies targeting key viral surface glycoproteins, as well as a robust cell-mediated immune response involving natural killer cells, CD4+ T cells, and CD8+ T cells. In immunocompromised patients, CMV disease may result from reactivation of the latent virus, primary infection, or reinfection with a different strain. Reactivation is primarily due to impaired cell-mediated immunity rather than a deficiency in humoral immunity, as these patients typically have sufficient levels of anti-CMV antibodies.[5] The inability to control CMV replication in these patients is mainly due to dysfunctional CD4+ and CD8+ T-cell responses, including impaired mono- and polyfunctional cytokine production. Additionally, CMV encodes proteins that disrupt immune defenses by interfering with class I and class II HLA presentation, natural killer cell activity, the cell cycle, and key apoptotic and inflammatory pathways that generally help contain the virus[17]

Histopathology

Histopathological diagnosis of CMV infection in any tissue can be made by identifying cytomegalic cells and CMV inclusion bodies, which are visible when stained with hematoxylin and eosin (H&E). These cells measure 25 to 35 µm in size, with basophilic intranuclear inclusions that are occasionally surrounded by a clear halo; intracytoplasmic inclusions can also be observed.[5] Finding these cytomegalic cells can be tedious and requires an astute pathologist, as well as a sufficient number of biopsy samples for evaluation.[5] The advent of immunohistochemical staining using anti-CMV monoclonal antibodies is the gold standard for making a diagnosis.[5][58][59]

In CMV-associated pneumonitis, lymphocytes and inflammatory cytokines populate the pulmonary interstitium, impairing gas exchange and leading to hypoxia and oxygen desaturation for the host.[60]

In GI CMV infection, mucosal infection by CMV leads to inflammation and tissue necrosis, vascular endothelial involvement, and, ultimately, ischemic mucosal injury. The occlusion of the vasculature contributes mainly to the cause of tissue injury and ulcer formation.[5] In CMV esophagitis, there are no specific endoscopic features that can confirm the diagnosis; therefore, the definitive diagnosis depends on biopsy findings. The diagnosis of CMV colitis requires histological examination of biopsy tissues taken from the base or edge of the ulcer. Patients with punched-out ulcers typically have a higher number of inclusion bodies on histology.[61] Histological examination can differentiate CMV colitis from other causes, eg, infectious colitis, ulcerative colitis, or drug-induced colitis.[62] Colonic mucosal biopsies stained with H&E may show viral inclusion bodies characteristic of CMV colitis, commonly referred to as owl eye inclusions, which are highly specific for CMV. However, H&E staining has limited sensitivity and is less reliable than immunohistochemistry, which is considered the gold standard for diagnosing CMV colitis.[59]

History and Physical

In healthy individuals, CMV infection is often asymptomatic and subclinical, typically resolving with minimal sequelae and a self-limiting course. When symptoms occur, the infection can present as a mononucleosis-like syndrome, including fever, fatigue, rash, and lymphadenopathy.[5] Rarely, symptoms can be prolonged, and on occasion, severe CMV infection may lead to sequelae, such as myocarditis, pneumonitis, and GI involvement.[63]

CMV infection in immunosuppressed patients can result in viremia and/or end-organ damage, affecting any organ. Clinical signs and symptoms are related to the organ affected by CMV. The affected organ may be the transplanted organ, resulting in impaired function and even graft rejection, or another organ that can exhibit dysfunction. Examples of these may be CMV pneumonitis in the case of a lung transplant recipient who presented with respiratory symptoms or CMV nephritis in a patient who had undergone a lung transplant, who presented with hematuria.[64][65]

CMV infection can occur anywhere in the GI tract in immunosuppressed patients.[5] In CMV esophagitis, the typical large, distal solitary or multiple esophageal ulcers typically produce symptoms such as odynophagia, dysphagia, and substernal chest pain.[5][66][49] Other symptoms include nausea, vomiting, abdominal pain, weight loss, and diarrhea.[10] Rare presentations include GI bleeding and stricture formation.[5][67] Patients with CMV colitis present with nonspecific symptoms, including diarrhea, abdominal pain, fever, rectal bleeding, and weight loss.[45] The symptoms can mimic an exacerbation of IBD, making it challenging to distinguish between ulcerative colitis and CMV colitis solely based on clinical presentation.[68] A high index of suspicion is necessary, and laboratory investigations are essential in diagnosing CMV colitis. 

Evaluation

In immunocompetent patients with symptoms of CMV disease, including fever, malaise, and lymphadenopathy, a definitive diagnosis is rarely necessary. In patients who have received SOT or HSCT, serological testing for IgG of the donor and the recipient before the transplantation provides essential information regarding serostatus for risk-stratification of CMV infection. This testing should not be used for the diagnosis of acute infection, but serves to guide close monitoring and inform decisions regarding CMV preventive strategies.[69][70]

In immunosuppressed patients or those for whom a diagnosis is necessary, serum viral DNA identification is the preferred initial test for suspected CMV infection. Quantitative CMV DNA polymerase chain reaction (PCR) assays are the preferred method for viral detection and the most sensitive method for detecting CMV. High levels of DNA in blood in HSCT patients are a strong predictor of CMV disease and end-organ damage.[69][70][71]

CMV pp65 antigenemia, which detects the pp65 antigen in peripheral blood leukocytes, is a rapid and semi-quantitative method for diagnosing CMV infection. In transplant recipients, a positive pp65 assay is a strong predictor of progression to invasive CMV disease.[72][73]

Visualizing pathognomonic CMV inclusion bodies on histopathological examination is the gold standard for diagnosing tissue CMV disease. CMV DNA PCR can also be used to diagnose CMV disease in tissues, such as the detection of CMV in bronchoalveolar lavage fluid or lung tissue samples through virus isolation, histopathologic testing, and immunohistochemical analysis.[65]

Cytomegalovirus Gastrointestinal Disease

For the diagnosis of CMV GI disease, the identification of CMV in biopsy specimens using standard histopathologic or immunohistochemical stains has traditionally been considered the gold standard for confirming proven disease. Quantitative PCR methods are increasingly being evaluated and utilized on tissue specimens to support the diagnosis of tissue-invasive CMV disease.[20]

Cytomegalovirus Esophagitis

Endoscopy with biopsy is the most reliable modality for diagnosing CMV esophagitis.[12] Importantly, CMV can remain latent or be asymptomatic in immunocompetent hosts; therefore, the detection of CMV in tissue or body fluids does not necessarily indicate disease. Relying on serologic testing and anti-CMV antibodies is not helpful, as the disease correlates with defective cell-mediated immunity, rather than humoral immunity. Anti-CMV IgM indicates a recent infection, and anti-IgG can be present in most adults who have previously been infected with CMV. Blood and oropharyngeal viral cultures, even if obtained from patients with risk factors such as organ transplant recipients, can help identify those at high risk for developing the disease; however, they are not sensitive or specific for identifying active disease.[5]

The endoscopic appearance of CMV esophagitis ulcers is well-demarcated, vertical, or horizontal linear shallow ulcers at the mid to distal esophagus.[10] Ulcerations can be single or multiple, deep, and resemble cavitations, with associated features such as mucosal edema and nodularity.[12] The intervening mucosa between the ulcers is typically normal.[5][66] There are no pathognomonic endoscopic or pathological features for CMV disease; therefore, finding cytomegalic cells with CMV inclusion bodies is critical. Successful identification of CMV at a tissue level is associated with having an adequate number of samples and the expertise of the examining pathologist.[5] Immunohistochemistry to label specific CMV antigens is a useful adjunct modality when inclusion bodies are difficult to identify.[58] CMV esophagitis carries a poor prognosis, a high risk of recurrence, and a high rate of 1-year morbidity and mortality.[12]

Cytomegalovirus Colitis

In healthy subjects, CMV colitis is typically asymptomatic or causes self-limited disease but may result in chronic infection or a life-long carrier state with intermittent reactivation. Patients with CMV colitis present with nonspecific symptoms, including diarrhea, abdominal pain, fever, rectal bleeding, and weight loss. The most frequently observed symptoms in these patients include hematochezia and diarrhea. Therefore, a high index of suspicion is necessary, and laboratory investigations are essential in diagnosing CMV colitis. Several methods are possible, including antigenemia, endoscopy, histological examination of biopsy tissues, CMV culture, and quantitative PCR of tissue samples.

The diagnosis of CMV colitis requires histological examination of biopsy tissues taken from the base or edge of the ulcer. One of the significant endoscopic findings in CMV colitis is the presence of ulcerations with a well-defined, punched-out appearance, typically found in 70% to 80% of patients.[68][74] However, ulcerations may be irregular and may also have a cobblestone-like appearance. An ulcer of the cecum involving the ileocecal valve is proposed as a specific finding in CMV colitis in patients with GVHD.[75]

Patients with punched-out ulcers typically have a higher number of inclusion bodies on histology.[61] Histological examination can differentiate CMV colitis from other causes, eg, infectious colitis, ulcerative colitis, or drug-induced colitis.[62] Colonic mucosal biopsies stained with H&E may reveal viral inclusion bodies characteristic of CMV colitis, commonly referred to as owl eye inclusions, which are highly specific for CMV. However, H&E staining has limited sensitivity and is less reliable than immunohistochemistry, which is considered the gold standard for diagnosing CMV colitis.[59] Diagnosis of CMV colitis requires serologic testing and endoscopic biopsies to confirm the diagnosis.

Histopathology

The identification of CMV disease in H&E-stained tissue sections relies on the characteristic presence of viral inclusions, often described as having an owl's eye appearance. These inclusions are highly specific for CMV. However, CMV-specific immunohistochemistry is the gold standard for confirming CMV infection in tissue biopsies. Therefore, if H&E-stained sections are negative but there is a strong clinical suspicion of CMV colitis, immunohistochemistry staining should be performed to enhance diagnostic accuracy.[58] 

Real-Time Polymerase Chain Reaction 

Qualitative and quantitative PCR for CMV DNA in blood is the diagnostic test of choice due to its high sensitivity and specificity.[20] Efforts are being made to improve standardization and reduce variability across PCR testing platforms and assays. This variability arises due to differences in assays, sample size, extraction methods, amplicon size, and sample types, such as whole blood or plasma.[20]

Generally, caution is required when testing for blood viral load by PCR, as CMV DNA may be compartmentalized in tissue, especially in cases of CMV end-organ damage, and may be absent from the blood. In these cases, clinical utility is limited, as CMV DNA may be present in patients with active disease in tissue but is not detectable in blood. In contrast, serial PCR testing may offer greater clinical value by enabling the monitoring of viral dynamics over time and assessing disease progression or response to therapy.[20]

Cytomegalovirus Culture

CMV culture offers high sensitivity and specificity for diagnosing CMV colitis; however, its major limitation is the prolonged turnaround time, which can delay diagnosis and hinder timely treatment in vulnerable patients.[76]

Serologic Testing

The CMV IgG test helps determine prior exposure to the virus, understand the serostatus of patients, and risk-stratify them, especially immunosuppressed individuals. This test may indicate an acute systemic infection or reactivation, but it lacks specificity and sensitivity for diagnosing tissue-invasive disease.

pp65 Antigenemia Assay

The pp65 antigenemia assay is a laboratory test to detect CMV pp65 antigen, a structural viral protein, in peripheral blood leukocytes. This assay is primarily used to diagnose and monitor active CMV infection, particularly in immunocompromised patients. The pp65 antigenemia assay is valuable for the early detection of CMV viremia and for guiding preemptive antiviral therapy before the onset of clinical disease. This test may aid in the early detection of CMV viremia and help predict clinical outcomes in patients, particularly in cases of tissue-invasive disease, such as suspected CMV colitis. Although many centers now prefer quantitative CMV PCR due to its higher sensitivity and ease of automation, the pp65 assay remains clinically useful, especially in settings with established expertise in its interpretation and in non-neutropenic patients, where adequate leukocytes are available for analysis.[77][78] 

 Table. Cytomegalovirus Diagnostic Tests

Table

Abbreviations: CMV, cytomegalovirus; IgM, immunoglobulin M; IgG, immunoglobulin G; PCR, polymerase chain reaction.

Treatment / Management

Immunocompetent patients present with minimal or no symptoms, are self-limited, and do not require specific therapy other than symptomatic management. However, antiviral therapy should be considered in severe cases of CMV mononucleosis, CMV infection, and CMV disease in immunocompromised patients.[79][80] Toxicity is not uncommon when using these agents, and their risks must be weighed against the benefits of initiating treatment. Prophylaxis is considered for all high-risk patients. The treatment of CMV disease or CMV end-organ disease typically involves antiviral therapy. Patients should be monitored for treatment failure, in which cases, the potential causes, such as the emergence of resistance to therapy, should be considered. In such cases, testing for antiviral drug resistance should be performed.[81]

Prophylaxis is administered to prevent primary, reactivation, or recurrence of CMV infection. In contrast, preemptive therapy is given to asymptomatic CMV-infected patients who have had CMV detected on screening tests, as this may reduce CMV viral load.

Immunosuppressed patients, including those with HIV/AIDS, those on immunosuppressants, or those undergoing a SOT or HSCT, should be tested for CMV IgG serostatus, as they are at high risk for complications from CMV infection. Despite advances in CMV prevention and treatment, infection remains a significant complication in solid organ transplant and HSCT recipients, underscoring the importance of effective prophylaxis in these populations. Pre-transplant CMV serology status is the most widely used indicator that predicts the occurrence of CMV infection.[82] CMV infection occurs in up to 50% of high-risk SOT patients, typically when the organ is transplanted from a CMV-seropositive donor to a CMV-seronegative recipient (D+/R−), and in 17% of CMV-seropositive recipients (R+).[20][27] Risk factors for CMV infection or disease include a D+/R− serological status, seropositive recipients, administration of anti-thymocyte globulin due to its potent T–cell-depleting effects, induction with mycophenolic acid, steroid therapy, or polyclonal antibodies, advanced age of both donors and recipients, and a history of acute organ rejection.[28] Other factors affecting the severity of CMV infection include whether it is a primary infection, reactivation, or superinfection; the degree of immunosuppression; and whether the patient has undergone SOT or HSCT.[20]

Prevention

Recipients of solid organ transplants from CMV-seropositive donors (D+) who are at risk for CMV infection should receive prophylactic antiviral therapy, typically with valganciclovir or intravenous (IV) ganciclovir, along with routine virologic surveillance. The duration of prophylaxis is determined by the recipient's risk stratification..

High-risk patients (D+/R−) should receive prophylaxis for a minimum of 6 months, whereas intermediate-risk recipients (R+) are typically treated for 3 months. In low-risk individuals (D−/R−), a prophylactic course of at least 3 months is also generally advised to mitigate the risk of late-onset disease.[82]

Even with prophylaxis, however, CMV infections can still occur, and treatment can be challenging, even with the administration of standard-of-care first- and second-line antivirals.[82] Valganciclovir is the preferred agent due to its oral formulation, good bioavailability, and established efficacy; IV ganciclovir is used when vascular access is available.[82] Newer antivirals, such as letermovir, have shown non-inferiority to valganciclovir in preventing CMV disease. Letermovir is a first-in-class antiviral that has been explicitly approved for this indication.[83][84] Maribavir has also been used for prophylactic treatment and has less toxicity than valganciclovir.[84]

Despite preventive measures, CMV infection following SOT remains linked to a heightened risk of acute rejection and graft failure, increased mortality, and higher healthcare costs due to more frequent hospital readmissions, longer inpatient stays, and overall higher hospitalization costs.[29]

Currently, there are 6 Food and Drug Administration–approved antiviral agents used in the management of CMV infections. Maribavir and letermovir have been most recently added to the armamentarium for the prevention and treatment of CMV infection. Each antiviral targets different aspects of the viral replication cycle, thus inhibiting replication.[19][84][85][86][87]

• Ganciclovir: Ganciclovir is the treatment of choice, especially for severe cases of CMV infection. This agent is a guanosine nucleoside analog that is activated by the viral UL97 kinase, inhibiting viral DNA synthesis.
• Valganciclovir: Valganciclovir is an oral prodrug of ganciclovir. This agent can be administered orally in less severe CMV infections.
• Cidofovir: Cidofovir is a cytidine monophosphate analog that inhibits viral DNA polymerase independent of viral activation.
• Foscarnet: Foscarnet is a pyrophosphate analog that directly inhibits the viral UL54 DNA polymerase.
• Maribavir: Maribavir is a selective inhibitor of the viral UL97 kinase, with a distinct binding site and resistance profile compared to ganciclovir.[87]
• Letermovir: Letermovir was approved in 2017 for both prevention and treatment, and works by targeting the viral terminase complex (UL56-UL89), thereby inhibiting CMV DNA cleavage and packaging.

Treatment of Cytomegalovirus

Valganciclovir and ganciclovir are the first-line treatments for CMV infection. However, their use may be limited by hematologic toxicity or the development of antiviral resistance. Resistance to ganciclovir can occur through mutations in UL97, which impairs drug phosphorylation, or UL54, which encodes the viral DNA polymerase.[84]

Cidofovir and foscarnet are second-line agents, primarily used when resistance or toxicity limits the effectiveness of first-line therapy. Both drugs are administered IV and are associated with significant nephrotoxicity.[84][88][89] All of these antivirals ultimately target the viral DNA polymerase, and mutations in UL54 may confer cross-resistance to ganciclovir, cidofovir, and foscarnet.[84][87]

Letermovir, in contrast, is a CMV-specific antiviral with a different mechanism of action. This agent targets the pUL56 subunit of the terminase complex, inhibiting the final stage of viral DNA processing and packaging. Letermovir is well-tolerated, lacks hematologic or renal toxicity, and is available in both oral and IV formulations.[84][90]

Refractory Cytomegalovirus

Failure to achieve clinical or virologic response after at least 14 days of appropriately dosed antiviral therapy is defined as refractory or resistant CMV infection.[91][92] Although antiviral resistance is a recognized cause, refractory CMV can also occur in the absence of documented resistance, though data on such cases remain limited. Reported rates of antiviral-resistant CMV in SOT recipients range up to 18%, particularly among patients receiving prolonged or subtherapeutic antiviral therapy.[91]

Therapeutic management of CMV infections in SOT recipients remains challenging due to the limited efficacy to toxicity ratio of conventional antivirals and the complexity of transplant-related immunosuppression. Agents such as ganciclovir, foscarnet, and cidofovir are associated with significant adverse effects, including myelosuppression and nephrotoxicity, which can limit their utility. The recent availability of novel anti-CMV therapies, including maribavir and letermovir, along with investigational approaches such as adoptive CMV-specific T-cell therapy, offers promising alternatives that may enhance viral control and improve outcomes in patients with refractory or recurrent CMV infections, respectively.[84][88][89] The benefit of these alternative therapies lies in their distinct mechanisms of action compared to existing antivirals, which reduces the risk of cross-resistance, their lower adverse effects compared to existing antivirals, and their specificity to CMV.[93] Letermovir has traditionally been used for prophylaxis due to the low threshold for resistance developing during CMV replication, whereas mirabavir has evidence in treating refractory CMV.[94][95] Both letermovir and mirabavir have drug-drug interactions that should be reviewed before administration, as letermovir interacts with CYP2C8, CYP3A, and CYP2C19 enzymes, and mirabavir inhibits P-glycoprotein and CYP2C9 activity.[96][97]

Cytomegalovirus Esophagitis

The mainstay of CMV esophagitis treatment is ganciclovir and valganciclovir.[17] The treatment of active disease should begin with induction therapy using IV ganciclovir at a dose of 10 to 15 mg/kg/d, administered in 2 to 3 divided doses daily for 3 to 6 weeks, depending on clinical circumstances.[5][98] Maintenance therapy with IV ganciclovir at 5 mg/kg/d is indicated in cases with concurrent retinitis or recurrent GI disease after discontinuation of induction therapy. Relapse is unfortunately common, as the patients have a baseline, severely persistent immune deficiency most of the time, and treatment only suppresses the infection but does not eliminate it.[5] If recurrence occurs, repeat induction therapy should be performed, followed by maintenance treatment. Foscarnet is an alternative to ganciclovir in cases where resistance to the first-line treatment occurs. Failure of monotherapy calls for an attempt at combination therapy with IV ganciclovir and IV foscarnet.[5] Current treatments still consist of antivirals, such as ganciclovir and valganciclovir, but research into alternatives is ongoing.[5][98][99] 

Cytomegalovirus Colitis

The majority of immunocompetent patients with CMV colitis may require no treatment with antiviral medications. Due to the significant adverse effects associated with antiviral agents such as ganciclovir, including myelosuppression, hepatotoxicity, nephrotoxicity, and central nervous system toxicity, there is mixed evidence that antiviral therapy significantly improves outcomes in this population or attenuates the risk of colectomy.[100][101] However, antiviral treatment may be considered in select cases, particularly in males older than 55 with severe disease and underlying conditions that compromise immune function, such as HIV infection, diabetes mellitus, chronic kidney disease, or steroid- or biologic-refractory IBD.[102][103][104] In these cases, ganciclovir or valganciclovir may be considered for treatment.[59] The British Society of Gastroenterology guidelines recommend initiating antiviral therapy in moderate-to-severe colitis with histological features of high-density CMV in mucosal tissue, particularly in steroid-refractory cases. The American College of Gastroenterology, in its updated 2025 guidelines on the management of adult ulcerative colitis patients, recommends CMV investigation in cases of acute severe ulcerative colitis but does not provide treatment recommendations if CMV is detected.[105]

CMV reactivation, commonly observed in patients with severe or corticosteroid-resistant IBD, does not universally require antiviral therapy, as the virus is often non-pathogenic in these settings, and treatment may not provide clinical benefit. Antiviral therapy should be considered under the following circumstances:

• When CMV reactivation leads to CMV colitis and histological examination shows high-grade CMV density [106]
• Patients with low-grade CMV density who have corticosteroid-refractory disease or are corticosteroid-dependent
• A large endoscopically visible ulcer may indicate the need for antiviral therapy.

Importantly, there is a lack of high-quality evidence regarding the treatment of CMV colitis with antiviral agents, and it remains unclear whether this approach improves colectomy rates or mortality outcomes. Further research, including large randomized trials, is necessary to define subgroups that can benefit from treatment. Concomitant use of anti-tumor necrosis factor therapy with antiviral therapy may be considered to treat CMV reactivation in patients with ulcerative colitis. Ganciclovir is effective in treating and preventing CMV disease in patients undergoing bone marrow transplantation.[107] The identification of high-risk groups and the use of prophylactic therapy are currently topics of research.[108]

Differential Diagnosis

Mononucleosis-Type Cytomegalovirus Infection

• Early HIV infection
• Human herpesvirus 6 infection
• Viral hepatitis
• Autoimmune hepatitis
• Epstein-Barr virus infection
• Infectious mononucleosis

Cytomegalovirus Esophagitis

CMV esophagitis typically presents as a single, large, isolated ulcer in the distal esophagus but can also manifest as diffuse esophagitis.[5] The diffuse presentation can be challenging to distinguish from other disorders, such as herpes simplex virus (HSV) esophagitis and gastroesophageal reflux disease. The differentiating factor is that HSV esophagitis typically presents as multiple, small, shallow ulcers, rather than extensive ulcers. HSV esophagitis also affects the entire esophagus, whereas CMV esophagitis normally affects the mid-to-distal esophagus.[66]

• Achalasia
• Acid peptic disease
• Aphthous ulcers
• Barrett's esophagus
• Candidiasis
• Cryptococcosis
• Drug-induced dysphagia
• Epstein-Barr virus infection
• Esophageal cancer
• Gastroesophageal reflux disease
• Herpes simplex esophagitis
• Histoplasmosis
• Tuberculosis

Cytomegalovirus Colitis

The differential diagnosis for CMV colitis includes the following:

• Viral or bacterial gastroenteritis
• IBD
• Colorectal cancer
• Toxic megacolon
• Diverticulitis
• Irritable bowel disease
• Celiac disease
• GVHD

Prognosis

CMV infection in immunosuppressed patients is associated with significant morbidity and mortality. Recent studies have highlighted the impact of CMV infection across various immunocompromised populations. In many SOT patients, CMV infection has been linked to markedly increased mortality.[109] A study reported a 47% mortality rate in patients with CMV infection compared to 13% in those without.[109] After adjusting for confounding factors, CMV infection remained a strong independent predictor of mortality.[110] In HSCT recipients, CMV infection significantly contributes to mortality.[111] CMV infection often leads to prolonged hospitalization, a higher rate of medical complications, and significantly worse clinical outcomes. These risks highlight the importance of early detection, close monitoring, and, when indicated, timely antiviral therapy in high-risk patients.[112]

Cytomegalovirus Esophagitis

Upper GI CMV disease in immunocompromised individuals is associated with significant morbidity and a high risk of mortality, with some studies reporting 1-year mortality rates as high as 25%.[12] Risk factors for poor outcomes include profound immunosuppression, for example, in SOT or HSCT recipients, individuals with advanced HIV/AIDS, delayed diagnosis, and lack of antiviral treatment.[49] Clinical manifestations can range from odynophagia and GI bleeding to ulceration and perforation, particularly in the esophagus or stomach. Timely diagnosis through endoscopy with biopsy, followed by appropriate antiviral therapy, typically ganciclovir or valganciclovir, can significantly improve patient outcomes and reduce mortality. However, even with treatment, outcomes remain guarded in patients with severe underlying disease or multi-organ involvement.[49] 

Cytomegalovirus Colitis

The overall prognosis of CMV colitis is generally excellent. However, certain risk factors have been associated with poorer outcomes and increased mortality. In immunocompetent individuals, prognosis is influenced by age, with those older than 55 experiencing slightly higher mortality rates. The need for surgical intervention is also linked to a less favorable prognosis. Additionally, some studies have increased mortality from CMV colitis is associated with male gender and immunocompromising conditions, such as HIV infection and HSCT, more so than SOT. In immunocompromised patients, early diagnosis and prompt treatment significantly improve outcomes. Biochemically, anemia, elevated C-reactive protein levels, and low albumin levels have been associated with an increased risk of CMV colitis.[113] Patients who experience reactivation of CMV colitis within the context of ulcerative colitis typically have a worse prognosis. However, timely therapy can also greatly enhance clinical outcomes in this group.[106]

Complications

Tissue-invasive CMV disease affects various organ systems and can be life-threatening. CMV colitis presents with diarrhea, abdominal pain, and GI bleeding, and may progress to serious complications such as perforation or toxic megacolon. CMV pneumonitis is another severe manifestation, especially in transplant recipients, and presents with cough, dyspnea, and hypoxia, often with a high mortality rate.[114] Other forms of organ involvement include CMV hepatitis, causing liver dysfunction; esophagitis or gastritis, leading to odynophagia, nausea, and GI bleeding; and CMV retinitis, which causes painless vision loss and retinal necrosis, especially in individuals with advanced HIV/AIDS.[114] CMV encephalitis may also occur, resulting in confusion, seizures, and altered mental status.[114]

In solid organ transplant and bone marrow transplant recipients, CMV infection is strongly associated with graft dysfunction and rejection.[115] CMV infection can contribute to both acute and chronic graft rejection, including bronchiolitis obliterans in lung transplant patients and graft vasculopathy in heart transplant recipients.[115]

CMV infection also predisposes immunosuppressed individuals to secondary infections, as it suppresses overall immune function. This immunosuppressive effect can increase the risk of concurrent bacterial, fungal, and other viral infections, including Epstein-Barr virus–associated post-transplant lymphoproliferative disorder and invasive fungal infections, such as aspergillosis.[116][117]

Additionally, CMV can cause bone marrow suppression, leading to anemia, leukopenia, and thrombocytopenia. These hematologic complications are particularly concerning in patients already dealing with drug-induced cytopenias from immunosuppressive therapy.[112]

Cytomegalovirus Esophagitis

Malnutrition can develop in the setting of dysphagia and odynophagia, which can be devastating in the setting of severe illnesses.[10] If the esophageal CMV ulcerations become extensive and deep enough, perforation and massive GI bleeding can occur spontaneously or as a complication during endoscopy.[5][12] Stricture formation, while uncommon, has been reported to occur despite undergoing treatment with antivirals and even as the initial presentation of CMV esophagitis without prior known ulcers.[21] A case report noted the formation of a stricture severe enough to cause complete obliteration of the esophageal lumen in a patient who had completed antiviral treatment and whose post-treatment pathology samples were negative for CMV and HSV, demonstrating that strictures can form despite disease treatment and resolution.[21]

Complications of CMV infection include the following:[118][119]

• Chronic inflammation
• Large bowel perforation
• Toxic megacolon
• Pseudo-membrane formation
• Development of ischemic colitis
• Patients with CMV colitis complicating IBD may develop severe hemorrhage and colon perforation

Deterrence and Patient Education

Deterrence strategies are essential for preventing CMV infection among immunosuppressed individuals. The use of antiviral prophylaxis remains one of the primary deterrence strategies to prevent CMV reactivation, particularly in high-risk groups such as HSCT recipients. Preemptive therapy is another approach that involves frequent monitoring of CMV viral loads in patients at risk. Antiviral treatment is initiated as soon as viral replication is detected, thereby preventing the progression to symptomatic disease. Additionally, infection control measures, such as rigorous hand hygiene and proper handling of bodily fluids, are crucial, especially in healthcare settings where immunocompromised patients are present.

Patient education is equally important in minimizing the impact of CMV infection. Educating patients about their risk and the potential complications of CMV, such as end-organ damage and increased mortality, is vital, especially for those undergoing immunosuppressive treatments. Patients should be taught to recognize the early symptoms of CMV infection, such as fever, malaise, and organ-specific complaints, which enable timely medical intervention. Ensuring adherence to prescribed antiviral regimens is another key element; patients must understand that consistent medication use can prevent viral reactivation and severe complications. Furthermore, lifestyle counseling should be provided, emphasizing the importance of avoiding contact with individuals who are sick, practicing safe food handling, and maintaining proper hygiene.

Through a combination of medical deterrence strategies and comprehensive patient education, healthcare providers can significantly reduce the incidence, severity, and consequences of CMV infections in immunocompromised populations.

Enhancing Healthcare Team Outcomes

For immunocompromised patients, CMV infection can have significant morbidity and mortality. CMV can affect nearly any organ system, making an interprofessional approach essential for comprehensive care. Immunocompromised patients may be candidates for prophylactic therapy; however, careful consideration must be given to potential drug interactions, toxicity, and the risk of developing antiviral resistance.

Once CMV infection is diagnosed in an immunocompromised patient, long-term follow-up is critical. Ongoing monitoring ensures the timely detection of complications, effective management of medication adverse effects, and regular assessment for disease recurrence. In cases of CMV retinitis, regular follow-up with an ophthalmologist is necessary to prevent vision loss and monitor treatment response.[79]

The involvement of an interprofessional team is essential to improving outcomes in patients at risk for or diagnosed with CMV infections. Key members of this team include primary care providers, infectious disease specialists, transplant surgeons, transplant nurses, and clinical pharmacists and nurses.

This collaborative approach ensures comprehensive, patient-centered care, helping to optimize both prevention and treatment strategies for CMV-related diseases. 

Cytomegalovirus Esophagitis

The first step in improving outcomes for patients with CMV esophagitis is identifying those at risk. Primary care physicians play a crucial role in educating immunocompromised patients about potential complications, including CMV esophagitis. This education should also extend to individuals who are about to become immunocompromised, such as patients with newly diagnosed cancer preparing for chemotherapy, or those starting immunosuppressive therapy for autoimmune diseases. Primary care physicians should counsel patients on recognizing key symptoms of CMV esophagitis, including odynophagia, dysphagia, and retrosternal chest pain. For patients with HIV, emphasizing adherence to highly active antiretroviral therapy is critical to prevent CD4 count decline, which significantly increases the risk for opportunistic infections such as CMV esophagitis. All patients at risk should also receive guidance on universal precautions, particularly when handling bodily fluids and other potentially infectious materials.

If CMV esophagitis is suspected, primary care physicians should obtain a detailed history and perform a thorough physical examination, with particular attention to relevant risk factors. Patients should be referred to a gastroenterologist for an upper endoscopy with biopsy, as histopathologic confirmation is essential for diagnosis. A pathologist should review biopsy samples. If challenges arise during treatment or complications occur, infectious disease specialists should be consulted for assistance in management.

Cytomegalovirus Colitis

The diagnosis and management of CMV colitis are complex and require a coordinated interprofessional approach. Key team members may include gastroenterologists, internists, infectious disease specialists, pathologists, clinical pharmacists, specialized nurses, oncologists, and transplant surgeons. A collaborative strategy is crucial for identifying high-risk patients, facilitating early diagnosis, and ensuring the prompt initiation of treatment.

Specialty-trained nurses play a vital role in educating patients on symptom recognition and ensuring adherence to clinical and serologic monitoring protocols, particularly in patients with solid organ transplants, to facilitate the early detection of infections. Clinical pharmacists and infectious disease specialists contribute by managing antiviral therapy, monitoring for toxicity, and identifying potential drug-drug interactions to prevent adverse events.

By working together, the interprofessional team can deliver optimal prophylaxis, monitoring, and treatment, ultimately improving clinical outcomes for patients at the highest risk of CMV colitis.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

Figure

Cytomegalovirus Retinitis. The image depicts a view of a fundus affected by cytomegalovirus retinitis. National Eye Institute, Public Domain, via Wikimedia Commons

References

1.Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, Griffiths P. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. Rev Med Virol. 2019 May;29(3):e2034. [PubMed: 30706584]2.Charles OJ, Venturini C, Gantt S, Atkinson C, Griffiths P, Goldstein RA, Breuer J. Genomic and geographical structure of human cytomegalovirus. Proc Natl Acad Sci U S A. 2023 Jul 25;120(30):e2221797120. [PMC free article: PMC10372631] [PubMed: 37459519]3.Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest. 2011 May;121(5):1673-80. [PMC free article: PMC3083799] [PubMed: 21659716]4.Fowler K, Mucha J, Neumann M, Lewandowski W, Kaczanowska M, Grys M, Schmidt E, Natenshon A, Talarico C, Buck PO, Diaz-Decaro J. A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development. BMC Public Health. 2022 Sep 01;22(1):1659. [PMC free article: PMC9435408] [PubMed: 36050659]5.Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med. 1993 Nov 01;119(9):924-35. [PubMed: 8215005]6.Forte E, Zhang Z, Thorp EB, Hummel M. Cytomegalovirus Latency and Reactivation: An Intricate Interplay With the Host Immune Response. Front Cell Infect Microbiol. 2020;10:130. [PMC free article: PMC7136410] [PubMed: 32296651]7.Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010 Jul;20(4):202-13. [PubMed: 20564615]8.Kotton CN, Torre-Cisneros J, International CMV Symposium Faculty. Aguado JM, Alain S, Baldanti F, Baumann G, Boeken U, de la Calle M, Carbone J, Ciceri F, Comoli P, Couzi L, Danziger-Isakov L, Fernández-Ruiz M, Girmenia C, Grossi PA, Hirsch HH, Humar A, Kamar N, Kotton C, Ljungman P, Malagola M, Mira E, Mueller N, Sester M, Teng CJ, Torre-Cisneros J, Ussetti P, Westall G, Wolf D, Zamora M. Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021. Transpl Infect Dis. 2022 Dec;24(6):e13977. [PMC free article: PMC10078482] [PubMed: 36271650]9.Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, Boeckh M, Fournier M, Hodowanec A, Komatsu T, Limaye AP, Manuel O, Natori Y, Navarro D, Pikis A, Razonable RR, Westman G, Miller V, Griffiths PD, Kotton CN., CMV Definitions Working Group of the Transplant Associated Virus Infections Forum. Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum. Clin Infect Dis. 2024 Sep 26;79(3):787-794. [PMC free article: PMC11426271] [PubMed: 39041385]10.Wang HW, Kuo CJ, Lin WR, Hsu CM, Ho YP, Lin CJ, Su MY, Chiu CT, Wang CL, Chen KH. The clinical characteristics and manifestations of cytomegalovirus esophagitis. Dis Esophagus. 2016 May;29(4):392-9. [PubMed: 25715747]11.Griffiths PD, Grundy JE. Molecular biology and immunology of cytomegalovirus. Biochem J. 1987 Jan 15;241(2):313-24. [PMC free article: PMC1147564] [PubMed: 3036059]12.Marques S, Carmo J, Pinto D, Bispo M, Ramos S, Chagas C. Cytomegalovirus Disease of the Upper Gastrointestinal Tract: A 10-Year Retrospective Study. GE Port J Gastroenterol. 2017 Nov;24(6):262-268. [PMC free article: PMC5731150] [PubMed: 29255766]13.Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis. 2010 Jun 01;50(11):1439-47. [PMC free article: PMC11000537] [PubMed: 20426575]14.Banerjee D, Deb R, Dar L, Mirdha BR, Pati SK, Thareja S, Falodia S, Ahuja V. High frequency of parasitic and viral stool pathogens in patients with active ulcerative colitis: report from a tropical country. Scand J Gastroenterol. 2009;44(3):325-31. [PubMed: 19040190]15.Alvarado-Esquivel C, Hernández-Tinoco J, Sánchez-Anguiano LF, Ramos-Nevárez A, Cerrillo-Soto SM, Estrada-Martínez S, Martínez-Ramírez L, Pérez-Álamos AR, Guido-Arreola CA. Seroepidemiology of cytomegalovirus infection in pregnant women in Durango City, Mexico. BMC Infect Dis. 2014 Sep 05;14:484. [PMC free article: PMC4161908] [PubMed: 25190314]16.Alvarado-Esquivel C, Terrones-Saldivar MDC, Hernandez-Tinoco J, Munoz-Terrones MDE, Gallegos-Gonzalez RO, Sanchez-Anguiano LF, Reyes-Robles ME, Antuna-Salcido EI. Seroepidemiology of Cytomegalovirus Infection in Pregnant Women in the Central Mexican City of Aguascalientes. J Clin Med Res. 2018 Apr;10(4):337-344. [PMC free article: PMC5827919] [PubMed: 29511423]17.Emery VC. Cytomegalovirus: recent progress in understanding pathogenesis and control. QJM. 2012 May;105(5):401-5. [PMC free article: PMC3328974] [PubMed: 22198913]18.Zheng QY, Huynh KT, van Zuylen WJ, Craig ME, Rawlinson WD. Cytomegalovirus infection in day care centres: A systematic review and meta-analysis of prevalence of infection in children. Rev Med Virol. 2019 Jan;29(1):e2011. [PubMed: 30306730]19.Bartlett AW, Hall BM, Palasanthiran P, McMullan B, Shand AW, Rawlinson WD. Recognition, treatment, and sequelae of congenital cytomegalovirus in Australia: An observational study. J Clin Virol. 2018 Nov;108:121-125. [PubMed: 30300787]20.Limaye AP, Babu TM, Boeckh M. Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation. Clin Microbiol Rev. 2020 Dec 16;34(1) [PMC free article: PMC7920732] [PubMed: 33115722]21.Sheth A, Boktor M, Diamond K, Lavu K, Sangster G. Complete esophageal obliteration secondary to cytomegalovirus in AIDS patient. Dis Esophagus. 2010 Aug;23(6):E32-4. [PubMed: 20659143]22.Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007 Jul;40(2):125-36. [PubMed: 17530009]23.Shimada T, Higashida-Konishi M, Izumi K, Hama S, Oshige T, Oshima H, Okano Y. Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: a retrospective study. Sci Rep. 2022 Dec 03;12(1):20926. [PMC free article: PMC9719476] [PubMed: 36463264]24.Anders HJ, Goebel FD. Neurological manifestations of cytomegalovirus infection in the acquired immunodeficiency syndrome. Int J STD AIDS. 1999 Mar;10(3):151-9; quiz 160-1. [PubMed: 10340195]25.Dieterich DT, Rahmin M. Cytomegalovirus colitis in AIDS: presentation in 44 patients and a review of the literature. J Acquir Immune Defic Syndr (1988). 1991;4 Suppl 1:S29-35. [PubMed: 1848619]26.Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, Pikis A, Razonable RR, Miller V, Griffiths PD., Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. Clin Infect Dis. 2017 Jan 01;64(1):87-91. [PubMed: 27682069]27.Natori Y, Alghamdi A, Tazari M, Miller V, Husain S, Komatsu T, Griffiths P, Ljungman P, Orchanian-Cheff A, Kumar D, Humar A., CMV Consensus Forum. Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis. Clin Infect Dis. 2018 Feb 01;66(4):617-631. [PubMed: 29020339]28.Tang Y, Guo J, Li J, Zhou J, Mao X, Qiu T. Risk factors for cytomegalovirus infection and disease after kidney transplantation: A meta-analysis. Transpl Immunol. 2022 Oct;74:101677. [PubMed: 35901951]29.Hakimi Z, Aballéa S, Ferchichi S, Scharn M, Odeyemi IA, Toumi M, Saliba F. Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting. Transpl Infect Dis. 2017 Oct;19(5) [PubMed: 28599091]30.Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, Green JS, Saad A, Antin JH, Savani BN, Lazarus HM, Seftel M, Saber W, Marks D, Aljurf M, Norkin M, Wingard JR, Lindemans CA, Boeckh M, Riches ML, Auletta JJ. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016 May 19;127(20):2427-38. [PMC free article: PMC4874224] [PubMed: 26884374]31.Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002 Feb 01;185(3):273-82. [PubMed: 11807708]32.Schmidt-Hieber M, Tridello G, Ljungman P, Mikulska M, Knelange N, Blaise D, Socié G, Volin L, Blijlevens N, Fegueux N, Yakoub-Agha I, Forcade E, Maertens J, Chevallier P, Passweg J, Cornelissen J, Russell N, Craddock C, Bourhis JH, Marchand T, Reményi P, Cahn JY, Michallet M, Montoto S, Kröger N, Glaß B, Styczynski J. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT. Ann Hematol. 2019 Jul;98(7):1755-1763. [PubMed: 30993417]33.Jakharia N, Howard D, Riedel DJ. CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies. Curr Treat Options Infect Dis. 2021;13(3):123-140. [PMC free article: PMC8294301] [PubMed: 34305463]34.Moliya P, Singh A, Singh N, Kumar V, Sohal A. Insights into gastrointestinal manifestation of human immunodeficiency virus: A narrative review. World J Virol. 2025 Mar 25;14(1):99249. [PMC free article: PMC11612874] [PubMed: 40134843]35.Cheung TW, Teich SA. Cytomegalovirus infection in patients with HIV infection. Mt Sinai J Med. 1999 Mar;66(2):113-24. [PubMed: 10100416]36.Udeze A, Odebisi-Omokanye M, Ajileye T. Cytomegalovirus infection among Human Immunodeficiency Virus (HIV) infected individuals on highly active anti-retroviral therapy in North-Central Nigeria. Afr Health Sci. 2018 Dec;18(4):1057-1065. [PMC free article: PMC6354892] [PubMed: 30766572]37.Park SC, Jeen YM, Jeen YT. Approach to cytomegalovirus infections in patients with ulcerative colitis. Korean J Intern Med. 2017 May;32(3):383-392. [PMC free article: PMC5432807] [PubMed: 28490715]38.Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol. 2001 Jul;96(7):2137-42. [PubMed: 11467645]39.Lee HS, Park SH, Kim SH, Kim J, Choi J, Lee HJ, Kim WS, Lee JM, Kwak MS, Hwang SW, Yang DH, Kim KJ, Ye BD, Byeon JS, Myung SJ, Yoon YS, Yu CS, Kim JH, Yang SK. Risk Factors and Clinical Outcomes Associated with Cytomegalovirus Colitis in Patients with Acute Severe Ulcerative Colitis. Inflamm Bowel Dis. 2016 Apr;22(4):912-8. [PubMed: 26829410]40.Shukla T, Singh S, Tandon P, McCurdy JD. Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated With Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2017 May/Jun;51(5):394-401. [PubMed: 27875356]41.McCurdy JD, Jones A, Enders FT, Killian JM, Loftus EV, Smyrk TC, Bruining DH. A model for identifying cytomegalovirus in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015 Jan;13(1):131-7; quiz e7. [PubMed: 24993369]42.Sager K, Alam S, Bond A, Chinnappan L, Probert CS. Review article: cytomegalovirus and inflammatory bowel disease. Aliment Pharmacol Ther. 2015 Apr;41(8):725-33. [PubMed: 25684400]43.Domènech E, Vega R, Ojanguren I, Hernández A, Garcia-Planella E, Bernal I, Rosinach M, Boix J, Cabré E, Gassull MA. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis. 2008 Oct;14(10):1373-9. [PubMed: 18452205]44.Maconi G, Lombardini M, Furfaro F, Bezzio C, Zerbi P, Ardizzone S. Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis: effect of antiviral treatment. Eur J Gastroenterol Hepatol. 2014 Oct;26(10):1146-51. [PubMed: 25089547]45.Inayat F, Hussain Q, Shafique K, Tasleem SH, Hurairah A. Cytomegalovirus Colitis in Immunocompetent Patients. Cureus. 2016 Nov 08;8(11):e869. [PMC free article: PMC5145268] [PubMed: 27980888]46.Wada Y, Matsui T, Matake H, Sakurai T, Yamamoto J, Kikuchi Y, Yorioka M, Tsuda S, Yao T, Yao S, Haraoka S, Iwashita A. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum. 2003 Oct;46(10 Suppl):S59-65. [PubMed: 14530660]47.Criscuoli V, Casà A, Orlando A, Pecoraro G, Oliva L, Traina M, Rizzo A, Cottone M. Severe acute colitis associated with CMV: a prevalence study. Dig Liver Dis. 2004 Dec;36(12):818-20. [PubMed: 15646428]48.Karigane D, Takaya S, Seki Y, Mastumoto Y, Onose A, Kosakai A, Sugaya N, Mori T. Cytomegalovirus enteritis in immunocompetent subjects: a case report and review of the literature. J Infect Chemother. 2014 May;20(5):325-9. [PubMed: 24751234]49.Hoversten P, Kamboj AK, Wu TT, Katzka DA. Risk Factors, Endoscopic Features, and Clinical Outcomes of Cytomegalovirus Esophagitis Based on a 10-year Analysis at a Single Center. Clin Gastroenterol Hepatol. 2020 Mar;18(3):736-738. [PubMed: 31077832]50.Isaacson MK, Compton T. Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. J Virol. 2009 Apr;83(8):3891-903. [PMC free article: PMC2663263] [PubMed: 19193805]51.Reeves MB, Breidenstein A, Compton T. Human cytomegalovirus activation of ERK and myeloid cell leukemia-1 protein correlates with survival of latently infected cells. Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):588-93. [PMC free article: PMC3258610] [PubMed: 22203987]52.Nosotti M, Tarsia P, Morlacchi LC. Infections after lung transplantation. J Thorac Dis. 2018 Jun;10(6):3849-3868. [PMC free article: PMC6051843] [PubMed: 30069386]53.Faith SC, Durrani AF, Jhanji V. Cytomegalovirus keratitis. Curr Opin Ophthalmol. 2018 Jul;29(4):373-377. [PubMed: 29708927]54.Liu R, Baillie J, Sissons JG, Sinclair JH. The transcription factor YY1 binds to negative regulatory elements in the human cytomegalovirus major immediate early enhancer/promoter and mediates repression in non-permissive cells. Nucleic Acids Res. 1994 Jul 11;22(13):2453-9. [PMC free article: PMC308195] [PubMed: 8041605]55.Reeves MB, Compton T. Inhibition of inflammatory interleukin-6 activity via extracellular signal-regulated kinase-mitogen-activated protein kinase signaling antagonizes human cytomegalovirus reactivation from dendritic cells. J Virol. 2011 Dec;85(23):12750-8. [PMC free article: PMC3209367] [PubMed: 21937636]56.Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021 Dec;19(12):759-773. [PMC free article: PMC8223196] [PubMed: 34168328]57.Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA. 1989 Jun 23-30;261(24):3607-9. [PubMed: 2542634]58.Juric-Sekhar G, Upton MP, Swanson PE, Westerhoff M. Cytomegalovirus (CMV) in gastrointestinal mucosal biopsies: should a pathologist perform CMV immunohistochemistry if the clinician requests it? Hum Pathol. 2017 Feb;60:11-15. [PubMed: 27666768]59.Yerushalmy-Feler A, Padlipsky J, Cohen S. Diagnosis and Management of CMV Colitis. Curr Infect Dis Rep. 2019 Feb 15;21(2):5. [PubMed: 30771028]60.Grundy JE, Shanley JD, Griffiths PD. Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition? Lancet. 1987 Oct 31;2(8566):996-9. [PubMed: 2889962]61.Yang H, Zhou W, Lv H, Wu D, Feng Y, Shu H, Jin M, Hu L, Wang Q, Wu D, Chen J, Qian J. The Association Between CMV Viremia or Endoscopic Features and Histopathological Characteristics of CMV Colitis in Patients with Underlying Ulcerative Colitis. Inflamm Bowel Dis. 2017 May;23(5):814-821. [PubMed: 28426459]62.Chidlovskii E, Deroux A, Bernard S, Couturier P. Cytomegalovirus colitis mimicking rectal carcinoma in an immunocompetent elderly woman. BMJ Case Rep. 2016 May 10;2016 [PMC free article: PMC4885349] [PubMed: 27166009]63.Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J. 2008 Mar 27;5:47. [PMC free article: PMC2289809] [PubMed: 18371229]64.Carlier FM, Evrard P, Dumonceaux M. Cytomegalovirus nephritis in a lung transplant recipient: A case report. JHLT Open. 2023 Oct;1:100003. [PMC free article: PMC11935480] [PubMed: 40144580]65.Lee HY, Rhee CK, Choi JY, Lee HY, Lee JW, Lee DG. Diagnosis of cytomegalovirus pneumonia by quantitative polymerase chain reaction using bronchial washing fluid from patients with hematologic malignancies. Oncotarget. 2017 Jun 13;8(24):39736-39745. [PMC free article: PMC5503648] [PubMed: 28061469]66.Wilcox CM, Straub RF, Schwartz DA. Prospective endoscopic characterization of cytomegalovirus esophagitis in AIDS. Gastrointest Endosc. 1994 Jul-Aug;40(4):481-4. [PubMed: 7926541]67.Koc B, Bircan HY, Altaner S, Cinar O, Ozcelik U, Yavuz A, Kemik O. Massive Alimentary Tract Bleeding due to Cytomegalovirus Infection in an Elderly Patient. Infect Dis Rep. 2014 Aug 13;6(3):5512. [PMC free article: PMC4178269] [PubMed: 25276331]68.Levin A, Yaari S, Stoff R, Caplan O, Wolf DG, Israeli E. Diagnosis of Cytomegalovirus Infection during Exacerbation of Ulcerative Colitis. Digestion. 2017;96(3):142-148. [PubMed: 28848127]69.Duraisamy SK, Mammen S, Lakshminarayan SKR, Verghese S, Moorthy M, George B, Kannangai R, Varghese S, Srivastava A, Abraham AM. Performance of an in-house real-time PCR assay for detecting Cytomegalovirus infection among transplant patients from a tertiary care centre. Indian J Med Microbiol. 2018 Apr-Jun;36(2):241-246. [PubMed: 30084418]70.Moresco BL, Svoboda MD, Ng YT. A Quiet Disease With Loud Manifestations. Semin Pediatr Neurol. 2018 Jul;26:88-91. [PubMed: 29961530]71.Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003 Jan 15;101(2):407-14. [PubMed: 12393659]72.Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood. 1992 Sep 01;80(5):1358-64. [PubMed: 1325214]73.Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011 Feb;25(1):151-69. [PMC free article: PMC3340426] [PubMed: 21236396]74.Suzuki H, Kato J, Kuriyama M, Hiraoka S, Kuwaki K, Yamamoto K. Specific endoscopic features of ulcerative colitis complicated by cytomegalovirus infection. World J Gastroenterol. 2010 Mar 14;16(10):1245-51. [PMC free article: PMC2839178] [PubMed: 20222169]75.Matsuda K, Ono S, Ishikawa M, Miyamoto S, Abiko S, Tsuda M, Yamamoto K, Kudo T, Shimizu Y, Hayase E, Hashimoto D, Teshima T, Matsuno Y, Sakamoto N. Cecum ulcer is a reliable endoscopic finding in cytomegalovirus colitis concomitant with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2018 May;97(5):877-883. [PubMed: 29340759]76.Landry ML, Ferguson D. Comparison of quantitative cytomegalovirus antigenemia assay with culture methods and correlation with clinical disease. J Clin Microbiol. 1993 Nov;31(11):2851-6. [PMC free article: PMC266143] [PubMed: 8263166]77.Moses S, Malathi J, Singha NR, Bagyalakshmi R, Madhavan HN. Determination of human cytomegalovirus pp65 antigenemia among renal transplant patients. Indian J Nephrol. 2012 Sep;22(5):347-52. [PMC free article: PMC3544055] [PubMed: 23326044]78.Marchetti S, Santangelo R, Manzara S, D'onghia S, Fadda G, Cattani P. Comparison of real-time PCR and pp65 antigen assays for monitoring the development of Cytomegalovirus disease in recipients of solid organ and bone marrow transplants. New Microbiol. 2011 Apr;34(2):157-64. [PubMed: 21617827]79.Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, Humar A., The Transplantation Society International CMV Consensus Group. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. Transplantation. 2018 Jun;102(6):900-931. [PubMed: 29596116]80.Lancini D, Faddy HM, Flower R, Hogan C. Cytomegalovirus disease in immunocompetent adults. Med J Aust. 2014 Nov 17;201(10):578-80. [PubMed: 25390262]81.Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, Mullane KM, Kotton C, Lundgren J, Komatsu TE, Lischka P, Josephson F, Douglas CM, Umeh O, Miller V, Ljungman P., Resistant Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clin Infect Dis. 2019 Apr 08;68(8):1420-1426. [PMC free article: PMC7348585] [PubMed: 30137245]82.Huh K, Lee SO, Kim J, Lee SJ, Choe PG, Kang JM, Yang J, Sung H, Kim SH, Moon C, Seok H, Shi HJ, Wi YM, Jeong SJ, Park WB, Kim YJ, Kim J, Ahn HJ, Kim NJ, Peck KR, Kim MS, Kim SI. Prevention of Cytomegalovirus Infection in Solid Organ Transplant Recipients: Guidelines by the Korean Society of Infectious Diseases and the Korean Society for Transplantation. Infect Chemother. 2024 Mar;56(1):101-121. [PMC free article: PMC10990892] [PubMed: 38527780]83.Limaye AP, Budde K, Humar A, Vincenti F, Kuypers DRJ, Carroll RP, Stauffer N, Murata Y, Strizki JM, Teal VL, Gilbert CL, Haber BA. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. JAMA. 2023 Jul 03;330(1):33-42. [PMC free article: PMC10245286] [PubMed: 37279999]84.Imlay HN, Kaul DR. Letermovir and Maribavir for the Treatment and Prevention of Cytomegalovirus Infection in Solid Organ and Stem Cell Transplant Recipients. Clin Infect Dis. 2021 Jul 01;73(1):156-160. [PubMed: 33197929]85.Ngai JJ, Chong KL, Oli Mohamed S. Cytomegalovirus Retinitis in Primary Immune Deficiency Disease. Case Rep Ophthalmol Med. 2018;2018:8125806. [PMC free article: PMC6169215] [PubMed: 30327738]86.Mozaffar M, Shahidi S, Mansourian M, Badri S. Optimal Use of Ganciclovir and Valganciclovir in Transplanted Patients: How Does It Relate to the Outcome? J Transplant. 2018;2018:8414385. [PMC free article: PMC6167560] [PubMed: 30319817]87.Frange P, Leruez-Ville M. Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections. Med Mal Infect. 2018 Dec;48(8):495-502. [PubMed: 29650261]88.Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, Finke J, Cordonnier C, Link H, Ljungman P., Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002 Feb 15;99(4):1159-64. [PubMed: 11830461]89.Mattes FM, Hainsworth EG, Geretti AM, Nebbia G, Prentice G, Potter M, Burroughs AK, Sweny P, Hassan-Walker AF, Okwuadi S, Sabin C, Amooty G, Brown VS, Grace SC, Emery VC, Griffiths PD. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis. 2004 Apr 15;189(8):1355-61. [PubMed: 15073671]90.Marschall M, Stamminger T, Urban A, Wildum S, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother. 2012 Feb;56(2):1135-7. [PMC free article: PMC3264222] [PubMed: 22106211]91.Walti CS, Khanna N, Avery RK, Helanterä I. New Treatment Options for Refractory/Resistant CMV Infection. Transpl Int. 2023;36:11785. [PMC free article: PMC10600348] [PubMed: 37901297]92.Karantoni E, Zavras PD, Su Y, Fang J, Tamari R, Cho C, Perales MA, Stern A, Papanicolaou GA. Outcomes of Refractory Cytomegalovirus Infection in the First Year after Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 Jul;28(7):403.e1-403.e7. [PMC free article: PMC10243123] [PubMed: 35476955]93.Melendez DP, Razonable RR. Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus. Infect Drug Resist. 2015;8:269-77. [PMC free article: PMC4531042] [PubMed: 26345608]94.Hofmann E, Sidler D, Dahdal S, Bittel P, Suter-Riniker F, Manuel O, Walti LN, Hirzel C. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature. Transpl Infect Dis. 2021 Jun;23(3):e13515. [PubMed: 33210830]95.Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, Duarte RF, Florescu DF, Kamar N, Kumar D, Maertens J, Marty FM, Papanicolaou GA, Silveira FP, Witzke O, Wu J, Sundberg AK, Fournier M., SOLSTICE Trial Investigators. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. Clin Infect Dis. 2022 Sep 10;75(4):690-701. [PMC free article: PMC9464078] [PubMed: 34864943]96.Song IH, Ilic K, Murphy J, Lasseter K, Martin P. Effects of Maribavir on P-Glycoprotein and CYP2D6 in Healthy Volunteers. J Clin Pharmacol. 2020 Jan;60(1):96-106. [PMC free article: PMC6972521] [PubMed: 31385617]97.Burger DM, Nijboer L, Ghobreyal M, Maertens J, Blijlevens N, Hilbrands L, Baas MC, Ljungman P, Brüggemann RJM. Drug-Drug Interaction Management with the Novel Anti-Cytomegalovirus Agents Letermovir and Maribavir: Guidance for Clinicians. Clin Pharmacokinet. 2024 Nov;63(11):1529-1546. [PMC free article: PMC11573823] [PubMed: 39509076]98.Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT, Hardy WD, Polis MA, Deutsch TA, Feinberg J, Spector SA, Walmsley S, Drew WL, Powderly WG, Griffiths PD, Benson CA, Kessler HA. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Arch Intern Med. 1998 May 11;158(9):957-69. [PubMed: 9588429]99.Meesing A, Razonable RR. New Developments in the Management of Cytomegalovirus Infection After Transplantation. Drugs. 2018 Jul;78(11):1085-1103. [PubMed: 29961185]100.Hsieh CR, Wu RC, Kuo CJ, Yeh PJ, Yeh YM, Chen CL, Chiu CT, Chiu CH, Pan YB, Tsou YK, Le PH. Adequate antiviral treatment lowers overall complications of cytomegalovirus colitis among inpatients with inflammatory bowel diseases. BMC Infect Dis. 2024 Apr 26;24(1):443. [PMC free article: PMC11046852] [PubMed: 38671346]101.Kopylov U, Eliakim-Raz N, Szilagy A, Seidman E, Ben-Horin S, Katz L. Antiviral therapy in cytomegalovirus-positive ulcerative colitis: a systematic review and meta-analysis. World J Gastroenterol. 2014 Mar 14;20(10):2695-703. [PMC free article: PMC3949279] [PubMed: 24627606]102.Jones A, McCurdy JD, Loftus EV, Bruining DH, Enders FT, Killian JM, Smyrk TC. Effects of antiviral therapy for patients with inflammatory bowel disease and a positive intestinal biopsy for cytomegalovirus. Clin Gastroenterol Hepatol. 2015 May;13(5):949-55. [PubMed: 25283582]103.Yoshino T, Nakase H, Ueno S, Uza N, Inoue S, Mikami S, Matsuura M, Ohmori K, Sakurai T, Nagayama S, Hasegawa S, Sakai Y, Chiba T. Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis. 2007 Dec;13(12):1516-21. [PubMed: 17828781]104.Dieterich DT, Kotler DP, Busch DF, Crumpacker C, Du Mond C, Dearmand B, Buhles W. Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomized, double-blind, placebo-controlled multicenter study. J Infect Dis. 1993 Feb;167(2):278-82. [PubMed: 8380610]105.Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. Am J Gastroenterol. 2025 Jun 03;120(6):1187-1224. [PubMed: 40701556]106.Beswick L, Ye B, van Langenberg DR. Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis. Inflamm Bowel Dis. 2016 Dec;22(12):2966-2976. [PubMed: 27763950]107.Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991 Dec 05;325(23):1601-7. [PubMed: 1658652]108.Bhutani D, Dyson G, Manasa R, Deol A, Ratanatharathorn V, Ayash L, Abidi M, Lum LG, Al-Kadhimi Z, Uberti JP. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2015 Jan;21(1):159-64. [PMC free article: PMC4283200] [PubMed: 25445637]109.Linares L, Sanclemente G, Cervera C, Hoyo I, Cofán F, Ricart MJ, Pérez-Villa F, Navasa M, Marcos MA, Antón A, Pumarola T, Moreno A. Influence of cytomegalovirus disease in outcome of solid organ transplant patients. Transplant Proc. 2011 Jul-Aug;43(6):2145-8. [PubMed: 21839217]110.Gardiner BJ, Bailey JP, Percival MA, Morgan BA, Warner VM, Lee SJ, Morrissey CO, Kaye DM, Peleg AY, Taylor AJ. Incidence and severity of cytomegalovirus infection in seropositive heart transplant recipients. Clin Transplant. 2023 Jun;37(6):e14982. [PMC free article: PMC10909407] [PubMed: 36988473]111.Meng XY, Fu HX, Zhu XL, Wang JZ, Liu X, Yan CH, Zhang YY, Mo XD, Wang Y, Han W, Chen YH, Chen DB, Liu HX, Chang YJ, Xu LP, Liu KY, Huang XJ, Zhang XH. Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation. Ann Hematol. 2020 Nov;99(11):2659-2670. [PubMed: 32734550]112.Fernández S, Grafia I, Peyrony O, Canet E, Vigneron C, Monet C, Issa N, Decavele M, Moreau AS, Lautrette A, Lacave G, Morel G, Cadoz C, Argaud L, Statlender L, Azem K, Quenot JP, Lesieur O, Fernández J, Farrero M, Marcos MÁ, Lemiale V, Castro P, Azoulay É. Clinical characteristics and outcomes of immunocompromised critically ill patients with cytomegalovirus end-organ disease: a multicenter retrospective cohort study. Crit Care. 2024 Jul 16;28(1):243. [PMC free article: PMC11251242] [PubMed: 39014504]113.Alotaibi Y, AlLehibi A, Almtawa A, Alotaibi N, Alghamdi A, Alrajhi S, AlQutub A, AlEid A, Alamr A, Ibrahim BA, Alahmari M, Alhamidi H, Ahmad S, Alshammari F, Almotawa F, Altannir Y, Alghamdi A. Prevalence and Risk Factors of Cytomegalovirus Colitis in Inflammatory Bowel Disease Patients in Riyadh, Saudi Arabia: A Tertiary Center Experience. Saudi J Med Med Sci. 2023 Oct-Dec;11(4):305-313. [PMC free article: PMC10634466] [PubMed: 37970458]114.Mena Lora A, Khine J, Khosrodad N, Yeldandi V. Unusual Manifestations of Acute Cytomegalovirus Infection in Solid Organ Transplant Hosts: A Report of Two Cases. Case Rep Transplant. 2017;2017:4916973. [PMC free article: PMC5611867] [PubMed: 29085699]115.Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019 Sep;33(9):e13512. [PubMed: 30817026]116.Lam JKP, Azzi T, Hui KF, Wong AMG, McHugh D, Caduff N, Chan KH, Münz C, Chiang AKS. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56dimNKG2A+KIR- NK Cells and Contributes to Suboptimal Control of EBV in Immunosuppressed Children With Post-transplant Lymphoproliferative Disorder. Front Immunol. 2020;11:1231. [PMC free article: PMC7311655] [PubMed: 32625211]117.Agrawal A, Ison MG, Danziger-Isakov L. Long-Term Infectious Complications of Kidney Transplantation. Clin J Am Soc Nephrol. 2022 Feb;17(2):286-295. [PMC free article: PMC8823942] [PubMed: 33879502]118.Barling DR, Tucker S, Varia H, Isaacs P. Large bowel perforation secondary to CMV colitis: an unusual primary presentation of HIV infection. BMJ Case Rep. 2016 Dec 21;2016 [PMC free article: PMC5237779] [PubMed: 28003231]119.Hasegawa T, Aomatsu K, Nakamura M, Aomatsu N, Aomatsu K. Cytomegalovirus colitis followed by ischemic colitis in a non-immunocompromised adult: a case report. World J Gastroenterol. 2015 Mar 28;21(12):3750-4. [PMC free article: PMC4375603] [PubMed: 25834346]

Disclosure: Andrew Nguyen declares no relevant financial relationships with ineligible companies.

Disclosure: Mahmoud Shorman declares no relevant financial relationships with ineligible companies.

Copyright © 2025, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK459185PMID: 29083720 Share

Views

• PubReader
• Print View
• Cite this PageNguyen AD, Shorman M. Cytomegalovirus Infections. [Updated 2025 Dec 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.

In this Page

• Continuing Education Activity
• Introduction
• Etiology
• Epidemiology
• Pathophysiology
• Histopathology
• History and Physical
• Evaluation
• Treatment / Management
• Differential Diagnosis
• Prognosis
• Complications
• Deterrence and Patient Education
• Enhancing Healthcare Team Outcomes
• Review Questions
• References

Related information

• PMCPubMed Central citations
• PubMedLinks to PubMed

Similar articles in PubMed

• Vesicoureteral Reflux.[StatPearls. 2025]Vesicoureteral Reflux.Leslie SW, Aeddula NR. StatPearls. 2025 Jan
• Prescription of Controlled Substances: Benefits and Risks.[StatPearls. 2025]Prescription of Controlled Substances: Benefits and Risks.Preuss CV, Kalava A, King KC. StatPearls. 2025 Jan
• Shoulder Arthrogram.[StatPearls. 2025]Shoulder Arthrogram.Roberts CC, Escobar E. StatPearls. 2025 Jan
• Review Adenosine Deaminase Deficiency.[GeneReviews(®). 1993]Review Adenosine Deaminase Deficiency.Hershfield M, Tarrant T. GeneReviews(®). 1993
• Review Management of urinary stones by experts in stone disease (ESD 2025).[Arch Ital Urol Androl. 2025]Review Management of urinary stones by experts in stone disease (ESD 2025).Papatsoris A, Geavlete B, Radavoi GD, Alameedee M, Almusafer M, Ather MH, Budia A, Cumpanas AA, Kiremi MC, Dellis A, et al. Arch Ital Urol Androl. 2025 Jun 30; 97(2):14085. Epub 2025 Jun 30.

See reviews...See all...

Recent Activity

ClearTurn OffTurn On

• Cytomegalovirus Infections - StatPearlsCytomegalovirus Infections - StatPearls

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more... Follow NCBI Twitter Facebook LinkedIn GitHub NCBI Insights Blog

Connect with NLM

• Twitter
• Facebook
• Youtube

National Library of Medicine 8600 Rockville Pike Bethesda, MD 20894

Web Policies FOIA HHS Vulnerability Disclosure

Help Accessibility Careers

• NLM
• NIH
• HHS
• USA.gov